Taj For DoctorsTaj Doctor

About Us

Taj Brands

Diseases Health Tips  HIV/AIDS News Contact Us


  All News
  Clinical Research
  Critical Care
  Genetics / Biotech
  Men's Health
  Infectious Diseases
  Reproductive Health
  Respiratory Medicine
  Women's Health
Taj Brands

Therapeutic Index


Each tablet contains :

Stavudine ..................................30 mg
Lamivudine..............................150 mg

Lamovir-S is indicated for the treatment of HIV infection as part of combination therapy.


Stavudine is an analog of thymidine. It is phosphorylated by cellular kinases into active triphosphate. Stavudine triphosphate inhibits the HIV reverse transcriptase by competing with natural substrate, thymidine triphosphate. It also causes termination of DNA synthesis by incorporating into it.Simultaneous use of AZT is not recommended, as it can inhibit the intracellular phosphorylation of stavudine. Other anti-HIV drugs do not possess this property.


Adverse events

The main severe adverse effect is peripheral neuropathy, which can be corrected by reducing dosage. Stavudine has been shown in laboratory test to be genotoxic, but with clinical doses its carcinogenic effects are non-existent. It is also one of the most likely antiviral drugs to cause lipodystrophy, and for this reason it is no longer recommended as a component of first line therapy.



STAVUDINE is contra-indicated in patients with hypersensitivity to stavudine or to any of the components in the formulation.

Pregnancy and Lactation

Safety in pregnancy has not been established. Studies in animals suggest that stavudine is excreted in milk. Because of both the potential for HIV transmission and the potential for side-effects in breast-feeding infants, Stavudine is not recommended for use by breast-feeding mothers.

Less frequent cases of lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including  Stavudine and other antiretrovirals. Obesity and prolonged nucleoside exposure may be risk factors. The majority of cases reported have been in women and fatal lactic acidosis has been reported in pregnant women who received

 the combination of  Stavudine and didanosine with other antiretrovirals. Caution should be exercised when prescribing  Stavudine to patients with known risk factors for liver disease.

Patients with risk factors and those being given a combination of Aspen Stavudine, didanosine and hydroxyurea should be closely monitored for liver toxicity.

 Peripheral neuropathy is a dose-related clinical toxicity that is characterized by numbness, tingling or pain in the hands and feet. Therapy should be withdrawn immediately. Symptoms may temporarily worsen following discontinuation of Aspen Stavudine. Should symptoms resolve satisfactorily, then a lower dose therapy may be considered (see “DOSAGE AND DIRECTIONS FOR USE”).

Patients with either a history of neuropathy, or in the advanced stages of HIV infection or those using combination therapy of  Stavudine with didanosine, are at greater risk for peripheral neuropathy and should be monitored closely.

Pancreatitis, either fatal or non-fatal, has been reported in patients on combination therapy with didanosine (with or without hydroxyurea). Combination therapy should be suspended should pancreatitis be suspected and reinstitution of stavudine therapy alone, once diagnosis is confirmed, should be undertaken with particular caution and close patient monitoring.

Dosage: 1 tablet twice daily for patients weighing < 60 kg

Presentations:               MRP         Retailer         Stockist
               10 tablets       108.00          86.40              77.76
               60 tablets       611.00        488.80            439.92


         Copyright © 2004- 2006 TAJ Pharmaceuticals Limited. All Rights Reserved.

Site Requirements : Internet Explorer 5.0+ or Netscape 5.0+, Flash Player 5.0 & Real Player 8 Basic
To get in touch with us, call on 91-22-2637 4592, 91--22-2637 4593 or fax us at 91-22-2634 1274 

Terms and Conditions | Disclaimer | Privacy Policy | Sitemap | Feedback | FAQ